Results 181 to 190 of about 127,439 (309)

Correction: Discovery of protease inhibitors from bacteria as novel adjuvants for oral vaccine formulations. [PDF]

open access: yesFront Immunol
Coria LM   +5 more
europepmc   +1 more source

Use of Nanostructured Silica SBA-15 as an Oral Vaccine Adjuvant to Control Mycoplasma hyopneumoniae in Swine Production. [PDF]

open access: yesInt J Mol Sci, 2023
Storino GY   +11 more
europepmc   +1 more source

Nanopore Sequencing for HPV in Oropharyngeal Squamous Cell Carcinoma and Benign Tonsil Specimens

open access: yesOtolaryngology–Head and Neck Surgery, EarlyView.
Abstract Objectives Human papillomavirus (HPV) accounts for the majority of oropharyngeal squamous cell carcinoma (OPSCC) cases in the United States but understanding the prevalence of high‐risk HPV in oropharyngeal tissue remains poor. We evaluated nanopore sequencing, a novel rapid, and long‐read sequencing platform, on OPSCC tissue and tested it in ...
Mikayla G. Hubbard   +5 more
wiley   +1 more source

Kaposiform hemangioendothelioma: Diagnosis and treatment

open access: yesPediatric Investigation, EarlyView.
Vascular endothelial growth factor‐C (VEGF‐C)/vascular endothelial growth factor receptor‐3 (VEGFR‐3) and angiopoietin‐2 (Ang‐2)/tyrosine kinase with immunoglobulin‐like and EGF‐like domain 2 (TIE2) signaling pathways play an important role in lymphangiogenesis.
Yi Tian   +5 more
wiley   +1 more source

Evidence‐based guideline for clinical practice in the diagnosis, treatment, management, and prevention of recurrent wheezing in infants and toddlers in China

open access: yesPediatric Investigation, EarlyView.
ABSTRACT Wheezing is a common respiratory symptom in infants and toddlers, and recurrent wheezing is a significant respiratory disorder affecting this age group. Given the multifactorial etiology of recurrent wheezing, clinical practice lacks standardized diagnostic and therapeutic protocols. Recent years have witnessed substantial progress in clinical
Committee of Pediatrics   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy